Maraviroc (UK-427857)

Catalog No.S2003 Synonyms: Celsentri,UK-427857

For research use only.

Maraviroc (Celsentri,UK-427857) is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.

Maraviroc (UK-427857) Chemical Structure

CAS No. 376348-65-1

Selleck's Maraviroc (UK-427857) has been cited by 41 publications

Purity & Quality Control

Choose Selective CCR Inhibitors

Other CCR Products

Biological Activity

Description Maraviroc (Celsentri,UK-427857) is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
Targets
CCR5 [3]
(Cell-free assay)
MIP-1α [1]
(Cell-free assay)
RANTES [1]
(Cell-free assay)
MIP-1β [1]
(Cell-free assay)
3.3 nM 5.2 nM 7.2 nM
In vitro

Maraviroc inhibits MIP-1β-stimulated γ-S-GTP binding to HEK-293 cell membranes, indicating its ability to inhibit chemokine-dependent stimulation of GDP-GTP exchange at the CCR5/G protein complex. Maraviroc also inhibits the downstream event of chemokine-induced intracellular calcium redistribution, with IC50s ranging from 7 to 30 nM obtained against MIP-1β, MIP-1α and RANTES. In the same experiments, Maraviroc does not trigger release of intracellular calcium at concentrations up to 10 μM, indicating that it is devoid of CCR5 agonist activity. Consistent with this, Maraviroc fails to induce CCR5 internalization. Maraviroc is active at low nanomolar concentrations against HIV-1 Ba-L. Maraviroc inhibits all 200 pseudotyped viruses with a geometric mean IC90 of 13.7 nM. [1] At concentrations >1000 times the 50% inhibitory concentration, maraviroc did not inhibit other chemokine receptors (CCR1, 2, 3, 4, 7, and 8; CXCR1 and 2) to a clinically relevant degree[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa-P4 MkXFSpVv[3Srb36gZZN{[Xl? Mnm5RY51[WexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBz\WOxbXLpcoFvfCCFQ2K1JIV5eHKnc4Pl[EBqdiCqdX3hckBJ\UyjLWC0JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWOYT3QOEBk\WyuczDibY5lcW6pIITvJGhKXjFiZ4CxOlAh\XiycnXzd4lv\yCFSF:gZ4VtdHNiYomgZ4VtdC2lZXzsJIZ2e2mxbjDhd5NigSxiSVO1NEA:KDBwMECwNkDPxE1w NFX1NIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3NVQ5PCd-MUmxO|E1QDR:L3G+
HeLa-P4 NGrmXXVHfW6ldHnvckBie3OjeR?= NFm5XoszOCCqcoO= MWLBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEOFUkWgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEinTHGtVFQh[2WubIOgZ48u\XiycnXzd4lv\yCFRESgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDpcoZ2e2mxbjD0c{BJUVZiZ4CxNlAh\XiycnXzd4VlKGmwIFPIU{11[XRzMDDj[YxteyCjZoTldkAzOCCqcoOgZpkh[2WubD3j[YxtKG[3c3nvckBie3OjeTygTWM2OCB;IECuNFAxOiEQvF2u MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMki2OlMoRjJzMUK4OlY{RC:jPh?=
TZM-bl M1q0W2Z2dmO2aX;uJIF{e2G7 NXjTVXB4OyCmYYnz NGW0ZXZKdmirYnn0bY9vKG:oIFPDVlUhcW5iaIXtZY4hXFqPLXLsJINmdGy|IHnu[oVkfGWmIIfpeIghUEmYMTDCZYwhWjViYYPz[ZN{\WRiYYOgZY51cX[rcnHsJIFkfGm4aYT5JIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6geolz[WxiaX7m[YN1cW:wIIDy[U1qdmO3YnH0[YQhf2m2aDDj[YxteyCob3zsc5dm\CCkeTD2bZJidCCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFAxOiEQvF2u NGfKb5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC4NlA4OCd-MkiwPFIxPzB:L3G+
TZM-bl M1vMUWZ2dmO2aX;uJIF{e2G7 MWW0PEBpenN? NXjpXYxxSW62YXfvcol{fCCjY4Tpeol1gSCjZ3HpcpN1KEOFUkWgdoVk\XC2b4KgbY4hcHWvYX6gWHpONWKuIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEmYLUGgUWdEOjZvaX7keYNm\CClZXzsMYNmdGxiZoXzbY9vKGKndIfl[Y4hfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjDlfJBz\XO|aX7nJIh2dWGwIFjFT|I6OyClZXzsd{B1dyCWWl2tZowh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODByM{eg{txONg>? NULBdY1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM4OjNpPkK0OVY{PzJ|PD;hQi=>
TZM-bl MnjGSpVv[3Srb36gZZN{[Xl? MYS0PEBpenN? MUjBcpRi\2:waYP0JIFkfGm4aYT5JIFo[Wmwc4SgR2NTPSC{ZXPldJRweiCrbjDoeY1idiCWWl2tZowh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDITXYuOSC\VUKtbY5lfWOnZDDj[YxtNWOnbHyg[pV{cW:wIHLleJdm\W5idnnyZYwh\W64ZXzvdIUheHKxdHXpckBmgHC{ZYPzbY5oKGi3bXHuJGhGUzJ7MzDj[YxteyC2bzDUXm0u[mxiY3XscJMh[W[2ZYKgOFghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMECwOFMh|ryPLh?= NEjITJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|czOyd-MkS1OlM4OjN:L3G+
PM1 NXXkSodiSW62aY\pdoFtKGG|c3H5 NH\FO45CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFLhcEBqdm[nY4Tl[EBqdiCqdX3hckBRVTFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckwhUUN7MDC9JFAvODByNzFOwG0v MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5MUS4OEc,OTlzN{G0PFQ9N2F-
PM1 NYmwbFRlSW62aY\pdoFtKGG|c3H5 M4W0[|Uh\GG7cx?= NVfLcJU3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS0OUNT3k[ZBmdmSnboSgTGlXOSCEYT3MJIlv\mWldHXkJIlvKGi3bXHuJHBOOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geolzfXNiaX7m[YN1cW:wIH3lZZN2emWmIHHmeIVzKDViZHH5d{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAxOSEQvF2u NH7K[og9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEKzOFMxOCd-M{CyN|Q{ODB:L3G+
SupT1 MoXkRY51cX[rcnHsJIF{e2G7 MYW0PEBpenN? MUnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYuOSCrbn\lZ5Rm\CCrbjDoeY1idiCVdYDUNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKGmwZnXjeIl3cXS7IHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAxOTFizszNMi=> NV7SZW5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVY3PjlpPkK0N|E3PjZ7PD;hQi=>
TZM-bl MUXGeY5kfGmxbjDhd5NigQ>? MkTEOFghcHK| NHHZc|ZCdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QhS0OUNTDy[YNmeHSxcjDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJUVZvMTC5NnJYNWmwZIXj[YQh[2WubD3j[YxtKG[3c3nvckBj\XS5ZXXuJJZqemGuIHXueoVtd3CnIIDyc5RmcW5iZYjwdoV{e2mwZzDoeY1idiCKRVuyPVMh[2WubIOgeI8hXFqPLXLsJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAxOTNizszNMi=> MnO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO3NlMoRjJ2NU[zO|I{RC:jPh?=
CHO MUHGeY5kfGmxbjDhd5NigQ>? NYHLfoU4OiCqcoO= M17SSmRqe3CuYXPlcYVvfCCxZjDbNVI5UV2UQV7USXMh\nKxbTDoeY1idiCFQ2K1JJJm[2WydH;yJINw\XiycnXzd4VlKHerdHigS4FteGijaU[gbY4hS0iRIHPlcIx{KGGodHXyJFIhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkCwNVQh|ryPLh?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF|N{mzO{c,OjBzM{e5N|c9N2F-
TZM-bl NHfnRWJHfW6ldHnvckBie3OjeR?= M4TTRVQ5KGi{cx?= NWf5PIdYSW62YXfvcol{fCCjY4Tpeol1gSCjZ3HpcpN1KEOFUkWgdoVk\XC2b4KgbY4hcHWvYX6gWHpONWKuIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEmYLUGgTnIuTkxvaX7keYNm\CClZXzsMYNmdGxiZoXzbY9vKGKndIfl[Y4hfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjDlfJBz\XO|aX7nJIh2dWGwIFjFT|I6OyClZXzsd{B1dyCWWl2tZowh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODBzNjFOwG0v NY\LPFFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM4OjNpPkK0OVY{PzJ|PD;hQi=>
HOS NXTsdFBESW62aY\pdoFtKGG|c3H5 MUK1JIRigXN? MYfBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDDR3I2NWSncHXu[IVvfCCKSW[xJGJiNUxiaX7m[YN1\WRiaX6gbJVu[W5iSF;TJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC4aYL1d{Bqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgOUBl[Xm|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMECxPUDPxE1w MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ|NEOwNEc,OzB{M{SzNFA9N2F-
HOS NWe5TJNCSW62aY\pdoFtKGG|c3H5 M1nC[2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiQnGtUEBqdm[nY4Tl[EBqdiCKT2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBqdm[nY4Tpc44tKEmFNUCgQUAxNjByMjFOwG0v NFnIPHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[2OFkzOCd-MUm2OlQ6OjB:L3G+
MOLT4 NF7qdIhHfW6ldHnvckBie3OjeR?= MoLPNVUhdWmwcx?= MXjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEOFUkWgbY4hT3GrNTD0doFve2[nY4Tl[EBpfW2jbjDNU2xVPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJCVlSHUz3zeIlufWyjdHXkJGNiOitiaX7mcJV5KHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSCGQV3HU{BkcGGubHXu[4UtKEmFNUCgQUAxNjByMkKg{txONg>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MkOwPEc,OjN4OEKzNFg9N2F-
JC53-BL M1Hpe2FvfGm4aYLhcEBie3OjeR?= MkiyN{Bl[Xm| NGX2PI9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBES1J3LYTyc5Bq[yC{ZXPvcYJqdmGwdDDITXYyKE6OQnHsJJZqenW|IHnu[oVkfGWmIHnuJGpEPTNvQlygZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkA{KGSjeYOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFI5KM7:TT6= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF|N{mzO{c,OjBzM{e5N|c9N2F-
JC53-BL NHHaSmRCdnSrdnnyZYwh[XO|YYm= NFzzRYk{KGSjeYO= M17LUmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hUkN3Mz3CUEBk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFMh\GG7czDwc5N1KGmwZnXjeIlwdixiSVO1NEA:KDBwMECzJO69VS5? NIjzeZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESxO|A6QCd-MkC0NVcxQTh:L3G+
HOS NIjqWG1CdnSrdnnyZYwh[XO|YYm= MkXOOUBl[Xm| NIHyc2dCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBES1J3LXTldIVv\GWwdDDITXYyKFOIMU[yJIlv\mWldHXkJIlvKGi3bXHuJGhQWyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geolzfXNiaX7m[YN1cW:wIH3lZZN2emWmIHHmeIVzKDViZHH5d{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAxPDdizszNMi=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ|NEOwNEc,OzB{M{SzNFA9N2F-
NIH/3T3 NF\FRVZHfW6ldHnvckBie3OjeR?= MorFNUBpeg>? M3\5ZWRqe3CuYXPlcYVvfCCxZjDbNVI2UV1vUlHOWGVUKG[{b32gR2NTPSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIFnfGW{IEGgbJItKEmFNUCgQUAxNjByNUKg{txONg>? NEn0cWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyOVgyPid-Mkm0NlU5OTZ:L3G+
SupT1 NGDOZZlCdnSrdnnyZYwh[XO|YYm= MoTNOFghcHK| M3e1TGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iU4XwWFEh[2WubIOg[Zhxd3OnZDD0c{B{fXCncn7heIFvfCCocn;tJGhKXjFiaX7m[YN1\WRiaIXtZY4hOjl|VDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBncXKnZnz5JIx2[2moZYLhd4Uh[XO|YYmgZoF{\WRic3nu[4xmNWO7Y3zlJGhKXjFicnXwcIlk[XSrb36gZZN{[XluIFnDOVAhRSByLkCwOVUh|ryPLh?= M3XS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO4OFk5Lz5{NU[zPFQ6QDxxYU6=
TZM-bl NIHq[WNCdnSrdnnyZYwh[XO|YYm= NUT6V49bPDhiaILz Mo\5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgR2NTPS2mZYDlcoRmdnRiSFnWNUBUTjF4MjDpcoZm[3SnZDDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJZqenW|IHnu[oVkfGmxbjDt[YF{fXKnZDDh[pRmeiB2ODDodpMheG:|dDDpcoZm[3Srb36gZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFY4KM7:TT6= M{LyN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkO0N|AxLz5|MEKzOFMxODxxYU6=
HEK293 NILYbXlHfW6ldHnvckBie3OjeR?= NYDVOot[OTBibXnudy=> M4DBcGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiQ1PSOUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZ48u\XiycnXzd4lv\yCJYXzwbIEyPiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFKDTmTFV{1qdmS3Y3XkJINidGOrdX2g[ox2gCCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpMh\m:ubH;3[YQh[nliUlHOWGVUKGGmZHn0bY9vKGK7IH\seY8uPEGPLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMEC4JO69VS5? Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{M{SzNFAoRjNyMkO0N|AxRC:jPh?=
CHO NIj1O5JHfW6ldHnvckBie3OjeR?= NV7HVYlqOTBibXnudy=> MnfMRY51[WexbnnzeEBi[3Srdnn0fUBi\2GrboP0JGNEWjViKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJINwNWW6cILld5NqdmdiR3HsdIhiOTZiaX7jeYJifGWmIH\vdkAyOCCvaX7zJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVmFPXEWVLXnu[JVk\WRiY3HsZ4l2dSCvb3LpcIl7[XSrb36sJGlEPTBiPTCwMlAyOzFizszNMi=> MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{i0PVgoRjJ3NkO4OFk5RC:jPh?=
CHO NFm3[29HfW6ldHnvckBie3OjeR?= NVnsNGkxOTBibXnudy=> NFe2NnNKdmirYnn0bY9vKG:oIFPDVlUhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiUlHOWGVUNWmwZIXj[YQhcW62cnHj[YxtfWyjcjDDZVIsKG2xYnnsbZpifGmxbjDh[pRmeiBzMDDtbY5{KGK7IF\seY8uPCCDTTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyOVQ{KM7:TT6= NInQXlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOxOlY3QSd-MkSzNVY3Pjl:L3G+
HEK293 NGnEN|hHfW6ldHnvckBie3OjeR?= NYjPdJZuOS53IH3pcpM> MnnuTY5pcWKrdHnvckBw\iCqdX3hckBOSVSHMT3t[YRq[XSnZDDBV3AsKHWydHHr[UBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEGuOUBucW6|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFE4NjNizszNMi=> NHfWPHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K0NVAzQSd-MkOyOFExOjl:L3G+
A673 M2H5[pFJXFNiYYPzZZk> NXfsT5NweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 NHS4O4dyUFSVIHHzd4F6 M3XUV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NXrpPIlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MlfBdWhVWyCjc4PhfS=> MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{ NF2xfY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 MVrxTHRUKGG|c3H5 Mle5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> NHrPSGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NGS1O3NyUFSVIHHzd4F6 NXS0RoVCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC M4W5bZFJXFNiYYPzZZk> M4jjU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NVnpXVF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NFj0Xm5yUFSVIHHzd4F6 NX34Vo5NeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NGjNPHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC Mnm3dWhVWyCjc4PhfS=> MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{ MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NEXs[IVyUFSVIHHzd4F6 NUn3[W5PeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= M1jqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 M4PyTJFJXFNiYYPzZZk> MlPGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Assay
Methods Test Index PMID
Western blot cleaved caspase-3 / cleaved caspase-9 / cleaved PARP / XIAP / Survivin / c-IAP1 / c-IAP2 / Bax / Bad / Bcl2 / Bcl-xl 28469959
In vivo

The half-life values of Maraviroc are 0.9 hour in the rat and 2.3 hours in the dog. Following oral administration (2 mg/kg) to the dog, the Cmax (256 ng/ml) occurred 1.5 hours post-dose, and the bioavailability is 40%. For the rat, approximately 30% of the administered dose is absorbed from the intestinal tract. [1] Female RAG-hu mice are challenged vaginally with HIV-1 an hour after intravaginal application of the Maraviroc gel. Maraviroc gel treated mice are fully protected against vaginal HIV-1 challenge in contrast to placebo gel treated mice which all became infected. Vaginal administration of Maraviroc fully protects mice against HIV-1 vaginal challenge. While there is a clear pattern of CD4 T cell decline in placebo-gel treated and viral challenged mice, their levels are stable in mice receiving Maraviroc gel. [2]

Protocol (from reference)

Kinase Assay:

[1]

  • Inhibition of chemokine binding to CCR5:

    Binding of 125I-labeled MIP-1α, MIP-1β, and RANTES to CCR5 is measured using intact HEK-293 cells stably expressing the receptor or membrane preparations thereof. Briefly, cells are resuspended in binding buffer (50 mM HEPES containing 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin [BSA] and adjusted to pH 7.4) to a density of 2 × 106 cells/ml. For membrane preparations, phosphate-buffered saline (PBS)-washed cells are resuspended in lysis buffer (20 mM HEPES, 1 mM CaCl2, 1 tablet COMPLETE per 50 mL, pH 7.4) prior to homogenization in a Polytron hand-held homogenizer, ultracentrifugation (40,000× g for 30 min), and resuspension in binding buffer to a protein concentration of 0.25 mg/mL (12.5 μg of membrane protein is used in each well of a 96-well plate). 125I-radiolabeled MIP-1α, MIP-1β, and RANTES are prepared and diluted in binding buffer to a final concentration of 400 pM in the assay. Maraviroc dilutions are added to each well to a final volume of 100 μL, the assay plates incubate for 1 hour, and the contents filter through preblocked and washed Unifilter plates which are counted following overnight drying.

Cell Research:

[1]

  • Cell lines: PHA-stimulated PBMC or PM-1 cells
  • Concentrations: 0-1 μM
  • Incubation Time: 5 days or 7 days
  • Method:

    Drug susceptibility assays are performed in 24-well tissue culture plates. Duplicate eight-point dilution series of Maraviroc are prepared in DMSO and medium to yield a final DMSO concentration of 0.1% (vol/vol) in the assay. PHA-stimulated PBMC or PM-1 cells are infected with virus for 1 hour at 37 °C. Cells are subsequently washed once, and 3.6 × 105 PBMC or 2.0 × 105 PM-1 cells are added to each well of assay plates containing diluted Maraviroc. Plates are incubated for 5 days (lab-adapted strains) or 7 days (primary isolates) at 37 °C in a humidified 5% CO2 (vol/vol) atmosphere.

Animal Research:

[2]

  • Animal Models: Humanized BALB/c-Rag2−/−γc−/− and BALB/c-Rag1−/−γc−/− (RAG-hu) mice
  • Dosages: ~64 μg
  • Administration: A 25 μL volume of the gel formulation is carefully applied in to the vaginal vault of mice.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 513.67
Formula

C29H41F2N5O

CAS No. 376348-65-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04966429 Recruiting Drug: Maraviroc Post Stroke Cognitive Impairment Tel-Aviv Sourasky Medical Center|Hadassah Medical Center|Soroka University Medical Center May 1 2021 Phase 2
NCT04710199 Completed Drug: Maraviroc experimental group|Other: Standard treatment Virus Diseases Fundación Pública Andaluza para la gestión de la Investigación en Sevilla February 23 2021 Phase 2
NCT02881762 Completed Drug: Maraviroc Hepatitis C|Human Immunodeficiency Virus University of Maryland Baltimore|ViiV Healthcare June 1 2017 Phase 4
NCT02778204 Completed Drug: Maraviroc HIV Infections National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|ViiV Healthcare|GlaxoSmithKline June 5 2017 Phase 1
NCT02741323 Completed Drug: Maraviroc|Drug: Placebo HIV Infections|Kidney Diseases National Institute of Allergy and Infectious Diseases (NIAID) January 1 2017 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What’s the vehicle do you recommend to dissolve the compound for in vivo experiments?

Answer:
S2003 Maraviroc can be dissolved in 5% DMSO/castor oil at 62 mg/ml as suspension for oral administration. As to a clear solution for injection, following three vehicles at 10mg/ml will help: 1. 2% DMSO/castor oil; 2. 2%DMSO/sunflower oil; 3. 2%DMSO/30%PEG 300/ddH2O.

Tags: buy Maraviroc (UK-427857) | Maraviroc (UK-427857) ic50 | Maraviroc (UK-427857) price | Maraviroc (UK-427857) cost | Maraviroc (UK-427857) solubility dmso | Maraviroc (UK-427857) purchase | Maraviroc (UK-427857) manufacturer | Maraviroc (UK-427857) research buy | Maraviroc (UK-427857) order | Maraviroc (UK-427857) mouse | Maraviroc (UK-427857) chemical structure | Maraviroc (UK-427857) mw | Maraviroc (UK-427857) molecular weight | Maraviroc (UK-427857) datasheet | Maraviroc (UK-427857) supplier | Maraviroc (UK-427857) in vitro | Maraviroc (UK-427857) cell line | Maraviroc (UK-427857) concentration | Maraviroc (UK-427857) nmr